%0 Journal Article %A Joanna Miłkowska - Dymanowska %A Paulina Laskowska %A Piotr Łacwik %A Sebastian Majewski %A Paweł Górski %A Wojciech J. Piotrowski %A Adam J. Białas %T Low level of serum free triiodothyronine can be a predictor of long-term mortality after COPD exacerbations %D 2020 %R 10.1183/13993003.congress-2020.3287 %J European Respiratory Journal %P 3287 %V 56 %N suppl 64 %X Introduction: Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality globally. Exacerbations and comorbidities are important elements of the natural history of COPD. Among COPD comorbidities, thyroid disorders remain one of the commonly underdiagnosed. Additionally, thyroid hormones are widely available and relatively inexpensive parameters.Aim: The aim of our study was to assess the role of thyroid hormones as markers of mortality after COPD exacerbations.Material and Methods: We performed a retrospective data analysis of patients hospitalized with COPD exacerbation in our tertiary pulmonary clinic, who had thyroid hormone assessments performed. We excluded patients with previously diagnosed thyroid disorders in our analysis.Univariate and multivariate analyses were conducted to identify the risk factors. Significant variables were further analyzed with Receiver Operating Characteristic (ROC) curves and Kaplan-Meier method using the log-rank test.Results: We identified records of 54 patients hospitalized for a COPD exacerbation with thyroid hormone results available (56% females). Multivariate Cox analysis revealed low free triiodothyronine (fT3) as the only significant predictor of mortality (HR = 0,095, p=0,03). In ROC analysis, a cut-off value of 2,48 pmol/L was determined (AUC= 0.878, p<0.05). Kaplan-Meier analysis revealed that patients with lower fT3 had higher mortality rate, but the results were not statistically significant (p=0.069).Conclusions: The low fT3 level can be a prognostic factor of long-term mortality after COPD exacerbations.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 3287.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). %U